The knowledge in the field of prostate cancer is rapidly changing. These EAU guidelines on prostate cancer summarize the most recent findings and put them into clinical practice.

No abstract

18F-deoxyglucose PET does not allow for metabolic labeling in the majority of untreated primary prostate cancers. BPH and primary prostate cancer cannot be reliably differentiated on the basis of PET. Increased 18F-deoxyglucose accumulation occurs in some primary prostate tumors and in metastatic deposits of prostate cancer.

No abstract

What ' s known on the subject? and What does the study add? Intermittent androgen deprivation therapy (ADT) involves cycling ADT, allowing hormonal recovery during off-treatment periods. This could lead to a better quality of life during off-treatment periods and could delay progression to castration resistance. Safety and feasibility of intermittent ADT have been shown but tolerability and health-related quality of life improvement have been suggested but questioned by others. Results from randomized trials, including relapsing or mixed populations, have suggested intermittent ADT to be as effective as continuous ADT.In this study of only metastatic patients, no statistical difference in either overall survival or progression-free survival was shown between intermittent and continuous ADT and suggests that intermittent might be as safe as continuous castration. It could be an option in highly responding and well-informed metastatic patients even if no clear benefi t in health-related quality of life was shown. This intermittent modality could be of interest in metastatic patients with signifi cant treatment-induced side-effects. OBJECTIVE• To compare intermittent androgen deprivation therapy (ADT) and continuous ADT after 6 months of induction of ADT in patients with metastatic prostate cancer (PCa). PATIENTS AND METHODS• This is an open-label randomized multi-centre study conducted in 58 centres in Europe.• Patients with metastatic PCa and prostate-specifi c antigen (PSA) level > 20 ng/mL at selection were randomized after 6 months of induction of ADT (leuprorelin and fl utamide) if PSA level had decreased below 4 ng/mL.• Patients received either continuous or intermittent ADT. All patients were treated until signs of disease progression under treatment or until study end with a monthly central PSA determination and follow-up visits were performed every 3 months.• The primary endpoint was overall survival. Secondary endpoints included progression-free survival, health-related quality of life (QLQ C30 questionnaire) and safety criteria. RESULTS• Of 383 selected patients, 173 had a PSA level below 4 ng/mL after 6 months of induction of ADT and were randomized. Median overall survival (52 vs 42 months, P = 0.75) and median progression-free survival (15.1 vs 20.7 months, P = 0.74) were not signifi cantly different between continuous and intermittent ADT.• Although some differences in quality of life were observed, most of the functional and symptom scales showed no signifi cant difference between the two groups.• Signifi cantly fewer treatment -emergent adverse events occurred in the intermittent group ( P = 0.042), with the incidence of headache and hot fl ushes also lower. CONCLUSIONS• This fi rst randomized trial comparing continuous with intermittent ADT in metastatic PCa suggests that intermittent ADT might be as safe as continuous ADT.• It could be an option in highly responding and well-informed patients even if no clear benefi t in health-related quality of life was shown. KEYWORDShormonal therapy , interm...